Effect of Rimonabant on Glycemic Control in Insulin-Treated Type 2 Diabetes: The ARPEGGIO Trial

OBJECTIVE: To examine the efficacy and safety of rimonabant, a selective cannabinoid receptor type-1 antagonist, in patients with type 2 diabetes receiving insulin monotherapy. RESEARCH DESIGN AND METHODS: Patients (n = 368; A1C ≥7%) were randomized to 20 mg/day rimonabant or placebo in this 48-week...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Hollander, Priscilla A., Amod, Aslam, Litwak, León E., Chaudhari, Umesh
Format: Artigo
Sprog:Inglês
Udgivet: American Diabetes Association 2010
Fag:
Original Research
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2827517/
https://ncbi.nlm.nih.gov/pubmed/20009090
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc09-0455
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker